LitAlert ~~ GeneLit.com

    • Detection of BRCA1/2 pathogenic variants in patients with breast and/or ovarian cancer and their families. Analysis of 3458 cases from Lower Silesia (Poland) according to the diagnostic algorithm of the National Cancer Control Programme.
    • Doraczynska-Kowalik A, Michalowska D, Matkowski R, Czykalko E, Blomka D, Semeniuk M, Abrahamowska M, Janus-Szymanska G, Mlynarczykowska P, Szynglarewicz B, Pawlak I, Maciejczyk A, Laczmanska I.
    • Front Genet. 2022 Aug 3;12:941375. doi: 10.3389/fgene.2022.941375.
    • Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    • Zhang Y, Wu H, Yu Z, Li L, Zhang J, Liang X, Huang Q.
    • BMC Cancer. 2022 Aug 2;22(1):842. doi: 10.1186/s12885-022-09943-0.
    • Genetic and clinical characteristics of BRCA-associated hereditary breast cancer in the West region of Kazakhstan.
    • Aitmagambetova MA, Smagulova GA, Tuhvatshin RR, Zheksenova AN, Amanzholkyzy A.
    • Carcinogenesis. 2022 Aug 2:bgac068. doi: 10.1093/carcin/bgac068. Epub ahead of print.
    • Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    • Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES, Milenkova T, Kumar S, Dymond M, Brown J, Liu JF.
    • Clin Cancer Res. 2022 Aug 2:CCR-21-1733. doi: 10.1158/1078-0432.CCR-21-1733. Epub ahead of print.